


Mechanism of Action in Haemophilia B

HEMGENIX® is a gene therapy that uses a recombinant AAV5 vector to deliver a functional copy of the *F9* gene to the hepatocytes of eligible adults with haemophilia B. The vector is specifically designed to follow a multi-step process of *in vivo*, liver-directed gene transfer with the goal of achieving elevated and sustained endogenous expression of functional factor IX through a single IV administration.^{1,2}



AAV5=adeno-associated virus serotype 5; FIX=factor IX; hFIX-Padua=Padua variant of human FIX

1. EU SmPC HEMGENIX® (European Medicines Agency, 2023).

2. Wang D, et al. *Nat Rev Drug Discov.* 2019;18(5):358-378.

Prescribing Information

Please refer to Summary of Product Characteristics available on www.ema.europa.eu for detailed information on HEMGENIX[®].

To report suspected adverse reactions, please visit www.cslbehring.com/contact.